What is the recommended management for non‑alcoholic fatty liver disease (NAFLD)?

Management of Non-Alcoholic Fatty Liver Disease (NAFLD)

The cornerstone of NAFLD management is achieving 5-10% weight loss through a Mediterranean diet combined with 150-300 minutes of moderate-intensity exercise weekly, with referral to weight management services or bariatric surgery for patients with obesity who fail dietary interventions. 1, 2

Lifestyle Modification: First-Line Therapy

Weight Loss Targets

• Aim for 5-10% weight loss: 5% improves steatosis, but 10% is needed to improve steatohepatitis and fibrosis 2
• Weight loss shows a dose-response relationship with NASH resolution, though less so for fibrosis 2

Dietary Approach

• Mediterranean diet is the most widely recommended due to documented reduction in hepatic fat content and positive cardiovascular effects 1
• Implement a hypocaloric diet (energy-restricted) as the primary strategy 1, 2
• Limit sugar intake aggressively 3
• Ensure adequate fiber intake to support microbiota health 3

Exercise Requirements

• 150-300 minutes of moderate-intensity exercise (3-6 metabolic equivalents) per week 2
• Alternative: 75-150 minutes of vigorous-intensity exercise weekly 2
• Exercise decreases aminotransferases and steatosis even without significant weight loss 2
• Aerobic treadmill-based training at 65-75% maximum heart rate is particularly effective 2

Structured Weight Management

Refer to weight management services for specialist dietetic support when dietary goals are not achieved 1. Office-based efforts during regular visits are typically insufficient—structured weight loss programs are more successful 2.

Risk Stratification Determines Intensity

Low-Risk Patients (FIB-4 <2.67)

• Focus on lifestyle modification
• Manage cardiovascular risk factors per standard guidelines
• Use statins—they are safe and beneficial in NAFLD 2
• For patients with type 2 diabetes: prioritize GLP-1 receptor agonists and SGLT2 inhibitors per American Diabetes Association guidelines 2
• Consider pioglitazone for improving cardiometabolic profile and reversing steatosis 2

High-Risk Patients (FIB-4 >2.67, LSM >12.0 kPa, or significant fibrosis on biopsy)

• Require hepatologist-led multidisciplinary team management 2
• Aggressive lifestyle changes with greater weight loss targets
• Monitor for cirrhosis, hepatocellular carcinoma, and cirrhosis-related complications 2
• Consider vitamin E 800 IU daily for biopsy-proven NASH without diabetes (mixed results in diabetics) 2
• Greater utilization of formal weight loss programs and anti-obesity medications 2

Bariatric Surgery

Refer for bariatric surgery consideration in NAFLD patients with obesity meeting national eligibility criteria 1. This is particularly important for patients with significant-advanced fibrosis who fail conservative management.

Evidence Supporting Bariatric Surgery:

• 85% NASH resolution rate at one year post-surgery 1
• Improves steatosis in 88% and steatohepatitis in 59% of patients 1
• Improves fibrosis in 30% of patients 1
• Reduces overall mortality from cardiovascular and malignant causes 1
• Safe even in patients with cirrhosis 1

The decision requires careful multidisciplinary evaluation, but bariatric surgery is currently underused despite robust histological evidence of benefit 1, 2.

Secondary Care Follow-Up Criteria

Patients requiring ongoing secondary care management include:

• Those with cirrhosis (F4)
• Significant-advanced fibrosis (F2-F3)
• Patients at risk of disease progression whose liver disease is not outweighed by comorbidities 1

These patients need:

• 6-monthly ultrasound surveillance for hepatocellular carcinoma 1
• Monitoring for ascites, varices, hepatic encephalopathy 1
• Consideration for investigational drugs or specific NASH treatments 1

Liver Transplantation

Consider transplant assessment for decompensated liver disease (jaundice, ascites, hepatic encephalopathy, variceal bleeding) 1.

Common Pitfalls to Avoid

• Don't wait for pharmacological approval—lifestyle modification is evidence-based first-line therapy now 4
• Don't underutilize bariatric surgery in appropriate candidates—it has robust mortality and histological benefits 1, 2
• Don't forget cardiovascular disease remains the leading cause of death in NAFLD patients, not liver disease 5
• Don't restrict vitamin E to only diabetic patients—evidence is strongest in non-diabetics with biopsy-proven NASH 2
• Don't manage high-risk patients (FIB-4 >2.67) in primary care alone—they require hepatology involvement 2